Estradiol acetate is under clinical development by Viramal and currently in Phase II for Menopausal Disorders. According to GlobalData, Phase II drugs for Menopausal Disorders have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Estradiol acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Estradiol acetate overview
Estradiol acetate is under development for menopausal hormone therapy. It is administered through the vaginal and transdermal route in the form of a cream. The therapeutic candidate acts by targeting the estrogen receptor. It is developed based on the viraderm transdermal technology.
Viramal overview
Viramal, is a pharmaceutical and healthcare company that primarily focuses on the development of biological and vaginal well-being products for women. The company’s main activities include research and development, in-licensing, and acquisition of technologies to create a portfolio of products. Viramal’s major products includes replens, a vaginal moisturiser, and Crinone, a bioadhesive vaginal gel containing micronized progesterone. Its products are used in the treatment of menopausal hormone therapy, fertility, contraception, and sexual health. The company provides prescription drugs and non-prescription drugs. It operates in the UK and Sweden. Viramal is headquartered in London, England, the UK.
For a complete picture of Estradiol acetate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
